Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00687674 · OUTCOME

Change in VEGF Expression Levels and Correlation With Clinical Outcomes (Phase II)

Sorafenib, Lenalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma · Source last updated 2019-08-20

This outcome was registered, but no numerical results were posted in the captured record.

Measure
Not reported
Unit
Not reported
Interval / dispersion
Not reported
Time frame
Post treatment

Groups in this outcome

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Reported measurements

No numerical measurement classes were posted for this outcome. Missing is not zero.

Complete source fields
denom Units Selected
Participants
reporting Status
NOT_POSTED
time Frame
Post treatment
title
Change in VEGF Expression Levels and Correlation With Clinical Outcomes (Phase II)
type
SECONDARY

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice